Kinnate Biopharma Inc.
KNTE · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $799 | $604 | $123 | $83 |
| Gross Profit | -$799 | -$604 | -$123 | -$83 |
| % Margin | – | – | – | – |
| R&D Expenses | $90,767 | $88,150 | $67,166 | $29,237 |
| G&A Expenses | $0 | $30,371 | $22,945 | $6,764 |
| SG&A Expenses | $27,442 | $30,371 | $22,945 | $6,764 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $348 | -$5 |
| Operating Expenses | $118,209 | $118,521 | $90,111 | $36,001 |
| Operating Income | -$119,008 | -$118,521 | -$90,111 | -$36,001 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $6,359 | $2,250 | $348 | $240 |
| Pre-Tax Income | -$112,649 | -$116,271 | -$89,763 | -$35,761 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$112,649 | -$114,021 | -$89,415 | -$35,433 |
| % Margin | – | – | – | – |
| EPS | -2.42 | -2.59 | -2.05 | -0.81 |
| % Growth | 6.6% | -26.3% | -153.1% | – |
| EPS Diluted | -2.42 | -2.59 | -2.05 | -0.81 |
| Weighted Avg Shares Out | 46,575 | 44,066 | 43,601 | 43,477 |
| Weighted Avg Shares Out Dil | 46,575 | 44,066 | 43,601 | 43,477 |
| Supplemental Information | – | – | – | – |
| Interest Income | $8,527 | $0 | $348 | $245 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $799 | $604 | $123 | $83 |
| EBITDA | -$118,209 | -$117,917 | -$89,988 | -$35,918 |
| % Margin | – | – | – | – |